Doug Hampton 
ABU DHABI, UAE , June 9, 2023 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a new Memorandum of Understanding (MoU) with leading global biopharmaceutical company MSD GCC, to advance research into breast and lung cancer. DoH MoU with MSD GCC DoH MoU with … Read more
Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in CLL Six-year median follow-up from the Phase 3 CLL14 study shows continued PFS after treatment with venetoclax plus obinutuzumab compared to treatment with chlorambucil plus obinutuzumab in previously untreated patients with CLL … Read more
NEW YORK, June 9, 2023 /PRNewswire/ — The global medical billing outsourcing market size is estimated to increase by USD 11,704.49 million from 2022 to 2027. The market’s growth momentum will be progressing at a CAGR of 15.73%. Discover some insights on market size, historic period (2017 to 2021), and Forecast (2023 to 2027) before buying the full report – Request a … Read more
It is through food that these two naturally occurring metals would increase the size of tumors. The study conducted in France by Dr Raphaël Rodriguez with researchers from the Institut Curie, the National Center for Scientific Research (CNRS) and the National Institute of Health and Medical Research (Inserm), was presented at the annual Chicago Cancer … Read more
Faron Pharmaceuticals Oy (“Faron” or “the Company”) Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells and antigen presentation Clinical activity across indications, with objective responses in 5 … Read more
Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated improvement of relapse-free survival (RFS) in a subgroup of patients with measurable residual disease (MRD) TOKYO and ROCKVILLE, Md., June 9, 2023 /PRNewswire/ — Astellas Pharma … Read more
CHICAGO, June 9, 2023 /PRNewswire/ — The Insect Repellent Active Ingredients Market is estimated at USD 1.0 billion in 2023 and is projected to reach USD 1.5 billion by 2028, at a CAGR of 7.6% from 2023 to 2028 according to a report published by MarketsandMarkets™. The rise in insect-borne diseases, such as malaria, dengue fever, Zika … Read more
the essential CiTique, a participatory research program on ticks in France, posted a tracking, which identifies tick bites. Between 2017 and 2023, more than 72,000 have been reported. And these bites do not only happen during outdoor outings, they happen for almost a third of them in familiar places. Every summer, the ticks come back. … Read more
CHENGDU, China, June 9, 2023 /PRNewswire/ — On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent … Read more
NEW YORK, June 9, 2023 /PRNewswire/ — The pharmaceutical contract research and manufacturing (CRAM) market size is forecast to increase by USD 121.35 billion from 2022 to 2027, at a CAGR of 10.32%, according to the recent market study by Technavio. The growth of the market depends on several factors, including the availability of cost-efficient resources in emerging … Read more